2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Xanthine Oxidase

Xanthine Oxidase

XO

Xanthine Oxidase

Related Products

PDF 0.47 MB

Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.

Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14268R
    Febuxostat (Standard)
    		Inhibitor
    Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat (Standard)
  • HY-B0219S
    Allopurinol-d2
    		Inhibitor 99.36%
    Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect.
    Allopurinol-d<sub>2</sub>
  • HY-14268S
    Febuxostat-d9
    		Inhibitor 98.70%
    Febuxostat-d9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with a Ki of 0.6 nM.
    Febuxostat-d<sub>9</sub>
  • HY-141508
    Flazin
    		Inhibitor 99.64%
    Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO-), with an IC50 value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC50 value of 71.99 μM for ONOO-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor.
    Flazin
  • HY-131268
    O-Desisobutyl-O-n-propyl Febuxostat
    		Inhibitor
    O-Desisobutyl-O-n-propyl Febuxostat, extracted from the patent CN 103467412, is an xanthine oxidase inhibitor.
    O-Desisobutyl-O-n-propyl Febuxostat
  • HY-B1135S
    Benzbromarone-d5
    		Inhibitor 99.42%
    Benzbromarone-d5 is deuterium labeled Benzbromarone.
    Benzbromarone-d<sub>5</sub>
  • HY-153972
    URAT1&XO inhibitor 2
    		Inhibitor 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
    URAT1&XO inhibitor 2
  • HY-14669
    Niraxostat
    		Inhibitor 98.54%
    Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved.
    Niraxostat
  • HY-19657S
    Oxypurinol-13C,15N2
    		Inhibitor
    Oxypurinol-13C,15N2 is 15N and 13C labeled Oxypurinol (HY-19657). Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
    Oxypurinol-<sub>13</sub>C,<sub>15</sub>N<sub>2</sub>
  • HY-14268A
    Febuxostat sodium
    		Inhibitor
    Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout.
    Febuxostat sodium
  • HY-162910
    HDAC-IN-79
    		Inhibitor
    HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
    HDAC-IN-79
  • HY-W141392
    2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite
    		98.81%
    2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
    2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite
  • HY-146273
    Xanthine oxidase-IN-7
    		Inhibitor
    Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout.
    Xanthine oxidase-IN-7
  • HY-151975
    Xanthine oxidoreductase-IN-5
    		Inhibitor
    Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia.
    Xanthine oxidoreductase-IN-5
  • HY-150257A
    Xanthine oxidase-IN-11
    		Inhibitor
    Xanthine oxidase-IN-11 (XO8 analog) is an xanthine oxidase (XO) inhibitor.
    Xanthine oxidase-IN-11
  • HY-146297
    Xanthine oxidoreductase-IN-2
    		Inhibitor
    Xanthine oxidoreductase-IN-2 (Compound IVa) is a xanthine oxidoreductase (XOR) inhibitor with the IC50 of 7.2 nM. Xanthine oxidoreductase-IN-2 shows hypouricemic effects in mice.
    Xanthine oxidoreductase-IN-2
  • HY-154393
    2-Chloro-2'-deoxy-6-O-methylinosine
    2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
    2-Chloro-2'-deoxy-6-O-methylinosine
  • HY-14874S
    Topiroxostat-d4
    		Inhibitor
    Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
    Topiroxostat-d<sub>4</sub>
  • HY-161455
    Xanthine oxidase-IN-13
    		Inhibitor
    Xanthine oxidase-IN-13 (Compound 10) is a selective xanthine oxidase inhibitor (IC50: 149.56 μM for bovine xanthine oxidase). Xanthine oxidase-IN-13 can be used for research of inflammatory arthritis.
    Xanthine oxidase-IN-13
  • HY-155123
    Antioxidant agent-13
    		Inhibitor
    Antioxidant agent-13 (Compound 5f) is an antioxidant agent. Antioxidant agent-13 inhibits DPPH and FRAP with IC50s of 80.33 and 85.69 μM. Antioxidant agent-13 also inhibits LOX and XO enzymes with IC50s of 16.85 and 23.01 μM.
    Antioxidant agent-13
Cat. No. Product Name / Synonyms Application Reactivity